Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.
Location: United States, Massachusetts, Lexington
Employees: 11-50
Phone: +1 781-761-4904
Total raised: $7.79M
Founded date: 2004
Investors 2
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Hercules C... | htgc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.01.2015 | - | $7.79M | - |
Mentions in press and media 13
| Date | Title | Description |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 12.07.2022 | 'Approvability has been put to bed': Aldeyra says eye drop clears three dry eye signals en route to FDA | Aldeyra’s attempt at treating dry eye disease has seen a few ups and downs in recent years, but the biotech’s sight to approval got a little clearer Tuesday with a crossover trial success that will pad its case to the FDA this qua... |
| 02.02.2022 | Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber | ModelLEXINGTON, Mass. - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, announced that results from the randomized, ... |
| 09.11.2021 | Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance - Form 8-K | Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance Top-Line Results from TRANQUILITY Expected This Quarter Toge... |
| 02.11.2021 | Aldeyra Therapeutics Corporate Overview – November 2021 | November 2021 CORPORATE OVERVIEW Innovative Approaches to Regulating Immune Response Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2021 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during th... |
| 28.10.2021 | Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights - Form 8-K | Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights Company Expects to Report Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease in the ... |
| 28.10.2021 | Aldeyra Therapeutics Corporate Overview – October 2021 | October 2021 CORPORATE OVERVIEW Innovative Approaches to Regulating Immune Response Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2021 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during thi... |
| 14.05.2021 | Aldeyra Therapeutics : Corporate Overview – May 2021 | May 2021 CORPORATE OVERVIEW Innovative Approaches to Regulating Immune Response Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2021 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this pr... |
| 14.05.2021 | ALDEYRA THERAPEUTICS, INC. Aldeyra Therapeutics : Corporate Overview – May 2021 | May 2021 CORPORATE OVERVIEW Innovative Approaches to Regulating Immune Response Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2021 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this pr... |
Show more